Bio-View Ltd (TLV: BIOV)

Market Cap	37.47M
Revenue (ttm)	34.34M
Net Income (ttm)	887.00K
Shares Out	127.01M
EPS (ttm)	0.01
PE Ratio	48.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,613
Open	30.60
Previous Close	30.40
Day's Range	29.10 - 30.60
52-Week Range	21.90 - 37.00
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2025

About Bio-View

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company’s products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies var...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 33
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BIOV

Financial Performance

In 2023, Bio-View's revenue was 34.77 million, an increase of 19.29% compared to the previous year's 29.15 million. Earnings were 383,000, a decrease of -34.75%.